File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

Title‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
Authors
Issue Date2022
PublisherBMC. The Journal's web site is located at http://arthritis-research.com/
Citation
Arthritis Research & Therapy, 2022, v. 24 How to Cite?
AbstractBackground The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p<0.001) and HDAS-ever (adjusted hazard ratio (HR) [95% CI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.
Persistent Identifierhttp://hdl.handle.net/10722/319248

 

DC FieldValueLanguage
dc.contributor.authorKandane-Rathnayake, R-
dc.contributor.authorLouthrenoo, W-
dc.contributor.authorHoi, A-
dc.contributor.authorLuo, SF-
dc.contributor.authorWu, YJJ-
dc.contributor.authorChen, YH-
dc.contributor.authorCho, J-
dc.contributor.authorLateef, A-
dc.contributor.authorHamijoyo, L-
dc.contributor.authorNavarra, S-
dc.contributor.authorZamora, L-
dc.contributor.authorSockalingam, S-
dc.contributor.authorAn, Y-
dc.contributor.authorLi, Z-
dc.contributor.authorKatsumata, Y-
dc.contributor.authorHarigai, M-
dc.contributor.authorHao, Y-
dc.contributor.authorZhang, Z-
dc.contributor.authorKikuchi, J-
dc.contributor.authorTakeuchi, T-
dc.contributor.authorBasnayake, BMDB-
dc.contributor.authorChan, M-
dc.contributor.authorNg, KPL-
dc.contributor.authorTugnet, N-
dc.contributor.authorKumar, S-
dc.contributor.authorOon, S-
dc.contributor.authorGoldblatt, F-
dc.contributor.authorO'Neill, S-
dc.contributor.authorGibson, K-
dc.contributor.authorOhkubo, N-
dc.contributor.authorTanaka, Y-
dc.contributor.authorBae, SC-
dc.contributor.authorLau, WCS-
dc.contributor.authorNikpour, M-
dc.contributor.authorGolder, V-
dc.contributor.authorMorand, EF-
dc.date.accessioned2022-10-14T05:09:51Z-
dc.date.available2022-10-14T05:09:51Z-
dc.date.issued2022-
dc.identifier.citationArthritis Research & Therapy, 2022, v. 24-
dc.identifier.urihttp://hdl.handle.net/10722/319248-
dc.description.abstractBackground The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p<0.001) and HDAS-ever (adjusted hazard ratio (HR) [95% CI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.-
dc.languageeng-
dc.publisherBMC. The Journal's web site is located at http://arthritis-research.com/-
dc.relation.ispartofArthritis Research & Therapy-
dc.title‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study-
dc.typeArticle-
dc.identifier.emailLau, WCS: cslau@hku.hk-
dc.identifier.authorityLau, WCS=rp01348-
dc.identifier.doi10.1186/s13075-022-02756-3-
dc.identifier.hkuros338797-
dc.identifier.volume24-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats